Combined Target-based and Ligand-based Drug Design Approach as Tool to Define a Novel Pharmacophore Model of Human A3 Adenosine Receptor Antagonists: Pyrazolo[4,3-E]1,2,4-Triazolo[1,5-C]Pyrimidine Derivatives as a Key Study

A combined target-based and ligand-based drug design approach has been carried out to define a novel pharmacophore model of the human A3 receptor antagonists. High throughput molecular docking and comparative molecular field analysis (CoMFA) have been used in tandem to assemble a new target based pharmacophore model.